Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tapinarof. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR known ✓ | P35869 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tapinarof SCHEMBL918343 | 1.00 | AHR (1.00) | AHRPTGS1PTGS2ALOX5TTR | |
| Tapinarof SCHEMBL28021456 | 1.00 | AHR (1.00) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL25520054 | 0.88 | AHR (0.78) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL28988507 | 0.85 | AHR (0.73) | AHRTTRTUBB1KDM4EMEN1 | |
| SCHEMBL24988838 | 0.85 | AHR (0.73) | AHRTTRTUBB1KDM4EMEN1 | |
| SCHEMBL918908 | 0.85 | AHR (0.73) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL918909 | 0.85 | AHR (0.73) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL24988866 | 0.84 | AHR (0.71) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL20657984 | 0.82 | AHR (0.69) | AHRPTGS1PTGS2ALOX5TTR | |
| SCHEMBL24988842 | 0.82 | AHR (0.68) | AHRPTGS1PTGS2ALOX5TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| CN-119874486-A | Process for preparing hydrogenated benomyl and analogues thereof | 浙江六康生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-20240285550-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | Dermavant Sciences GmbH (CH) | 2024-08-29 | — | — | US | claimed |
| CN-114042041-B | topical pharmaceutical composition | 德玛万科学有限责任公司 | 2023-08-22 | — | — | CN | claimed |
| CN-114709406-B | Sulfur-rich copolymer material, lithium sulfur battery positive electrode material, and preparation methods and applications thereof | 中国电建集团成都勘测设计研究院有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-20230225987-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | Dermavant Sciences GmbH (CH) | 2023-07-20 | — | — | US | claimed |
| CN-112250546-B | Synthesis method of (E) -3, 5-dihydroxyl-4-isopropyl stilbene | 中山大学 | 2023-05-12 | — | — | CN | claimed |
| EP-4171529-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | Dermavant Sciences GmbH (CH) | 2023-05-03 | — | — | EP | claimed |
| US-20170231922-A1 | 3, 5-DIHYDROXY-4-ISOPROPYLSTILBENE (DHIS) AS MITICIDAL AGENT AND ITS THERAPEUTIC USES | HORIZON GENOMED THERAPEUTICS, INC. (CA) | 2017-08-17 | — | — | US | claimed |
| US-20160338973-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | DERMAVENT SCIENCES GMBH (CH) | 2016-11-24 | — | — | US | claimed |
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | claimed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | claimed |
| EP-1248774-B1 | POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTIPSORIATIC AGENTS AND PROTEIN KINASE INHIBITORS | WELICHEM BIOTECH INC (CA) | 2009-10-07 | — | — | EP | claimed |
| WO-2006004722-A2 | COMPOSITIONS AND METHODS FOR SELECTIVELY ACTIVATING HUMAN SIRTUINS | BIOMOL RESEARCH LABORATORIES, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | claimed |
| US-20030171429-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues | WELICHEMBIOTECH INC. (CA) | 2003-09-11 | — | — | US | claimed |
| CN-1407978-A | Anti-inflammatory, psoriasis treatment and protein kinase inhibition using hydroxystilbenes, novel stilbene derivatives and analogues thereof | GENHUI CHEN (CA) | 2003-04-02 | — | — | CN | claimed |
| WO-1995003695-A1 | NOVEL FUNGICIDAL PROPERTIES OF METABOLITES, CULTURE BROTH, STILBENE DERIVATIVES AND INDOLE DERIVATIVES PRODUCED BY THE BACTERIA XENORHABDUS AND PHOTORHABDUS SPP. | AGRO-BIOTECH CORPORATION (US) | 1995-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | AHR 1108/4885PTGS1 275/4885PTGS2 293/4885 |
| US-20160338973-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | TSLP, SQLE, DHCR7 | AHR 1517/4885PTGS1 201/4885PTGS2 338/4885 |
| US-20170231922-A1 | 3, 5-DIHYDROXY-4-ISOPROPYLSTILBENE (DHIS) AS MITICIDAL AGENT AND ITS THERAPEUTIC USES | CYP8B1, DHCR7, DHCR24 | AHR 2222/4885PTGS1 635/4885PTGS2 820/4885 |
| US-20230225987-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | TSLP, SQLE, DHCR7 | AHR 1517/4885PTGS1 201/4885PTGS2 338/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | AHR 1326/4885PTGS1 256/4885PTGS2 352/4885 |
| US-20240285550-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS | TSLP, SQLE, DHCR7 | AHR 1517/4885PTGS1 201/4885PTGS2 338/4885 |
| US-20030171429-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues | ROCK1, ROCK2, PTK2 | AHR 2205/4885PTGS1 430/4885PTGS2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.